PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

Shares :

0
(0)
  • Strengthens position to become a leader in the intradermal delivery of FDA prescription-based ketamine products
  • Supports commercializing novel uses and delivery methods of psychedelics

TORONTO, July 21, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining a novel formulation of ketamine for intradermal administration as potential treatments for mental health, neurological and pain disorders. The Company’s intellectual property portfolio includes 19 granted patent and patent applications filed in over 150 countries.

Fabio Chianelli, CEO of PharmaTher, commented: “As we continue to advance our clinical programs with ketamine, we are building a robust intellectual portfolio of potential prescription-based ketamine products and psychedelics through novel uses, formulations and delivery forms to treat various diseases and disorders. I am pleased with our continued dedication to becoming a leader of novel ketamine products and implementing a patent strategy that would protect our clinical development and commercialization initiatives.”

The patent application, entitled “Methods and Compositions of Ketamine Formulation for Intradermal Administration,” describes the potential improvement and therapeutic value of ketamine by delivering it through the skin. Intradermal drug delivery, defined as bypassing the outermost layer of the skin (the stratum corneum) by a suitable device (i.e. patch or spray) and depositing the drug in the underlying viable skin layers (the epidermis and dermis), is an attractive alternative drug delivery approach employed to overcome certain drug administration challenges present in oral, subcutaneous and intramuscular injections, intravenous, and intranasal delivery. Also, intradermal delivery methods and compositions provide the potential for significant reduction of skin irritation, rapid and controlled drug uptake, pharmacodynamics and pharmacokinetics, as well as improved bioavailability and deposition of the drug at a pre-specified volume.

BREAKING : Majic Acquires The $150M Calfin Global Crypto Exchange: CGCX | READ HERE

PharmaTher is positioning itself as an innovator of novel uses, formulations and delivery forms of ketamine. PharmaTher has a robust pharmaceutical pipeline including, an FDA approved IND to conduct a Phase 2 clinical trial evaluating ketamine to treat Parkinson’s disease, and upcoming clinical studies with KETABET™ (ketamine and betaine) for depression and ketamine for amyotrophic lateral sclerosis (Lou Gehrig’s disease).

The Company also focuses on incorporating psychedelics (i.e. ketamine, psilocybin, DMT, MDMA and LSD) in a microneedle patch with the potential to improve on the safety (i.e. fewer side effects), efficacy (i.e. bioavailability, optimized dosing regimen including continuous system delivery) and compliance (i.e. storage, distribution and self-administration) of these compounds.

In addition, the Company continues to evaluate novel uses of ketamine that would follow the FDA 505(b)(2) regulatory pathway targeting rare disorders that could receive orphan drug designation and large market indications that the FDA could grant fast track designation. As a result, certain PharmaTher current and future programs have the potential to meet the requirements for these FDA designations.

About PharmaTher Holdings Ltd.

​PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics to treat mental health, neurological and pain disorders. PharmaTher is currently conducting an FDA approved phase 2 clinical study with ketamine to treat Parkinson’s disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics.


Sign up for MORE news updates !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.


Shares :